Popular GLP-1 weight loss drugs like Ozempic and Zepbound may help lower a woman’s risk for 14 types of cancer, a new study suggests.Researchers compared GLP-1 ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric adverse events ...

Starting Jan. 1, Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 ...